WHO ICTRP trial
A randomized phase II trial comparing epirubicin, cisplatin, and capecitabine…
NL-OMON27982 · Overview of Medical Research in the Netherlands (NL-OMON) · Recruiting
Key facts
| Trial ID | NL-OMON27982 |
|---|---|
| Public title | A randomized phase II trial comparing epirubicin, cisplatin, and capecitabine versus the combination of epirubicin, cisplatin, and capecitabine with pravastatin in patients with irresectable or metastatic gastric carcinoma. |
| Scientific title | A randomized phase II trial comparing epirubicin, cisplatin, and capecitabine versus the combination of epirubicin, cisplatin, and capecitabine with pravastatin in patients with irresectable or metastatic gastric carcinoma. |
| Primary sponsor | Not applicable |
| Registry | Overview of Medical Research in the Netherlands (NL-OMON) |
| Recruitment status | Recruiting |
| Study type | Interventional |
| Conditions | advanced irresectable or metastatic gastric carcinoma |
| Interventions | Control arm (ECC): epirubicin 50 mg/m2 i.v., day 1, Cisplatin 60 mg/m2 i.v., day 1, 3-hour infusion, Capecitabine 1000 mg/m2 in the morning and 1000 mg/m2 in the evening, p.o., day 1-14. ECC will be given at 3-week intervals, for a maximum… |
| Registration date | Sep 20, 2005 |
| Target size | 43 |
| Secondary IDs | NL376;NTR416; : EMC 04-147;ISRCTN23062732 |
| Registry page | onderzoekmetmensen.nl |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: